PARK CITY, Utah, July 28, 2016 /PRNewswire/ -- Nutraceutical International Corporation (NASDAQ: NUTR) today reported results for the fiscal 2016 third quarter ended June 30, 2016. Net sales for the fiscal 2016 third quarter were $60.8 million, compared to $54.4 million for the same quarter of fiscal 2015. For the third quarter of fiscal 2016, net income was $6.0 million, or $0.65 diluted earnings per share, compared to net income of $4.5 million, or $0.47 diluted earnings per share, for the same quarter of fiscal 2015.

Net sales for the nine months ended June 30, 2016 were $176.3 million compared to $162.8 million for the same period of fiscal 2015. For the nine months ended June 30, 2016, net income was $14.9 million, or $1.59 diluted earnings per share, compared to net income of $11.9 million, or $1.24 diluted earnings per share, for the same period of fiscal 2015.

Operating cash flow for the nine months ended June 30, 2016 was $23.5 million, compared to $21.2 million for the same period of fiscal 2015. The operating cash flow for the nine months ended June 30, 2016, combined with net borrowings of $14.5 million and existing cash, was primarily used to invest $26.2 million in acquisitions of natural product businesses, $6.4 million in purchases of property, plant and equipment and $6.4 million in purchases of common stock for treasury.

Bill Gay, chairman and chief executive officer, commented, "Our fiscal 2016 third quarter net sales grew by 12% primarily as a result of stronger international sales as well as sales from acquisitions completed during this fiscal year. Third quarter net income increased by $1.5 million and Adjusted EBITDA increased by $2.3 million. Management believes that the strong results during our last two quarters reflect the leverage and synergies generated from increased net sales. We are hopeful that our international business will continue to improve during the balance of calendar 2016. We plan to continue to carefully work through the integration of our fiscal 2016 acquisitions, including completing the transition of operations into company-owned facilities, which will take some period of time to complete. We are pleased with the overall contributions these acquisitions have produced to date."

Mr. Gay continued, "We are actively pursuing complementary acquisitions that can leverage our physical and human infrastructure. The strength of our cash flow and banking relationships should enable management to follow its stated strategy of growing through acquisitions and investing in automation to lower costs. We are considering a number of internal initiatives that could assist management in limiting labor cost pressures through technology. We continue to consolidate our manufacturing and branded business operations into company-owned facilities to gain operational efficiencies. We believe that our branded product portfolio and innovative product formulations, along with our strength in manufacturing, distribution and sales, will continue to provide a solid foundation for the growth of our business in the healthy foods channel and other channels."

Mr. Gay added, "I am also pleased to announce that on July 26, 2016, our Board of Directors agreed to add an additional one million shares to our previously approved share purchase program, which means the Company is now authorized to buy up to approximately 1.2 million total additional shares of our outstanding common stock. Under this approved share purchase program, the Company may purchase common stock from time to time on the open market and in individually negotiated transactions. The amount and timing of any purchases will be dependent upon a number of factors, including the price and availability of the Company's shares and general market conditions. The Company currently has approximately 9.2 million shares of its common stock outstanding. The Company has purchased over 1.3 million shares in the last five fiscal years. We thank our customers, employees, and stockholders for continuing to support our long-term business strategy."

ABOUT NUTRACEUTICAL
We are an integrated manufacturer, marketer, distributor and retailer of branded nutritional supplements and other natural products sold primarily to and through domestic health and natural food stores. Internationally, we market and distribute branded nutritional supplements and other natural products to and through health and natural product distributors and retailers. Our core business strategy is to acquire, integrate and operate businesses in the natural products industry that manufacture, market and distribute branded nutritional supplements. We believe that the consolidation and integration of these acquired businesses provide ongoing financial synergies through increased scale and market penetration, as well as strengthened customer relationships.

We manufacture and sell nutritional supplements and other natural products under numerous brands, including Solaray®, KAL®, Dynamic Health(TM), Nature's Life®, LifeTime®, Natural Balance®, NaturalCare®, Health from the Sun®, Pioneer®, Nutra BioGenesis(TM), Life-flo®, Organix South®, Heritage Store® and Monarch Nutraceuticals(TM).

We own neighborhood natural food markets, which operate under the trade names The Real Food Company(TM), Thom's Natural Foods(TM), Cornucopia Community Market(TM) and Granola's(TM). We also own health food stores, which operate under various trade names, including Fresh Vitamins(TM) and Peachtree Natural Foods®.

We manufacture and/or distribute one of the broadest branded product lines in the industry, with approximately 7,500 SKUs, including approximately 750 SKUs exclusively sold internationally. We believe that, as a result of our emphasis on innovation, quality, loyalty, education and customer service, our brands are widely recognized in health and natural food stores and among their customers.

This Press Release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 with respect to our financial condition, results of operations and business. These forward-looking statements can be identified by the use of terms such as "believe," "expects," "plan," "intend," "may," "will," "should," "can," or "anticipates," or the negative thereof, or variations thereon, or comparable terminology, or by discussions of strategy. These statements involve known and unknown risks, uncertainties and other factors that may cause industry trends or our actual results to be materially different from any future results expressed or implied by these statements. Important factors that may cause our results to differ from these forward-looking statements include, but are not limited to: (i) changes in or new government regulations or increased enforcement of the same including adverse determinations by regulators; (ii) unavailability of desirable acquisitions, inability to complete them or inability to integrate them; (iii) increased costs, including from increased raw material or energy prices; (iv) changes in general worldwide economic or political conditions; (v) adverse publicity or negative consumer perception regarding nutritional supplements; (vi) issues with obtaining raw materials of adequate quality or quantity; (vii) litigation and claims, including product liability, intellectual property and other types; (viii) disruptions from or following acquisitions including the loss of customers; (ix) increased competition; (x) slow or negative growth in the nutritional supplement industry or the healthy foods channel; (xi) the loss of key personnel or the inability to manage our operations efficiently; (xii) problems with information management systems, manufacturing efficiencies and operations, including system interruptions and security/cybersecurity breaches; (xiii) insurance coverage issues; (xiv) the volatility of the stock market generally and of our stock specifically; (xv) increases in the cost of borrowings or unavailability of additional debt or equity capital, or both, or fluctuations in foreign currencies; and (xvi) interruption of business or negative impact on sales and earnings due to acts of God, acts of war, terrorism, bio-terrorism, civil unrest and other factors outside of our control. Copies of our SEC reports are available upon request from our investor relations department or may be obtained at the SEC's website (www.sec.gov).



                             NUTRACEUTICAL INTERNATIONAL CORPORATION

                              CONDENSED CONSOLIDATED BALANCE SHEETS

                                (unaudited; dollars in thousands)



                                                               June 30, September 30,
                                                               -------- -------------

                                                                                 2015

                                                                   2016

    Assets

         Current assets, net                                 $92,741

                                                                           $86,215

         Property, plant and
          equipment, net                                      83,399

                                                                            77,645

         Goodwill                                             30,925

                                                                            24,384

         Other non-current
          assets, net                                         29,530

                                                                            24,205
                                                                            ------

                                                                             $212,449

                                                               $236,595
                                                               --------


    Liabilities and
     Stockholders'
     Equity

         Current liabilities                                 $21,215

                                                                           $20,528

         Long-term
          liabilities                                         46,192

                                                                            31,674

         Stockholders'
          equity                                             169,188

                                                                           160,247
                                                                           -------

                                                                             $212,449

                                                               $236,595
                                                               --------



                                                        NUTRACEUTICAL INTERNATIONAL CORPORATION

                                                    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

                                               (unaudited; dollars in thousands, except per share data)



                                                                                    Three months ended June 30,           Nine months ended June 30,
                                                                                    ---------------------------           --------------------------

                                                                                             2016                  2015                    2016                  2015

    Net sales                                                               $60,836                    $54,382            $176,287                   $162,830

    Cost of sales                                                                          29,416                27,955                  86,430                83,293
                                                                                           ------                ------                  ------                ------

                                                 Gross profit                                31,420                26,427                  89,857                79,537

    Operating expenses

                                                  Selling, general and
                                                  administrative                             21,895                19,061                  64,016                58,404

                                                 Amortization of intangible assets              988                   729                   2,968                 2,189
                                                                                              ---

    Income from operations                                                                  8,537                 6,637                  22,873                18,944

    Interest and other
     expense, net                                                                             326                   257                     922                   827
                                                                                              ---                   ---                     ---                   ---

    Income before provision
     for income taxes                                                                       8,211                 6,380                  21,951                18,117

    Provision for income
     taxes                                                                                  2,182                 1,930                   7,063                 6,220
                                                                                            -----                 -----                   -----                 -----


    Net income                                                               $6,029                     $4,450             $14,888                    $11,897
                                                                             ------                     ------             -------                    -------



    Net income per common share

                                                 Basic                                        $0.65                 $0.47                   $1.59                 $1.24

                                                 Diluted                                       0.65                  0.47                    1.59                  1.24


    Weighted average common shares outstanding

                                                 Basic                                    9,310,097             9,561,008               9,390,765             9,612,171

                                                 Diluted                                  9,310,097             9,563,999               9,390,765             9,617,091





                                                    NUTRACEUTICAL INTERNATIONAL CORPORATION

                                                            ADJUSTED EBITDA SCHEDULE

                                                       (unaudited; dollars in thousands)



                     Three months ended June 30,          Nine months ended June 30,
                     ---------------------------          --------------------------

                                               2016                                  2015        2016      2015


    Net income                             $6,029                                $4,450     $14,888   $11,897

    Provision for
     income taxes                           2,182                                 1,930       7,063     6,220

    Interest and
     other expense,
     net (1)                                  326                                   257         922       827

    Depreciation and
     amortization                           3,579                                 3,195      10,599     9,702
                                            -----                                 -----      ------     -----


    Adjusted EBITDA                       $12,116                                $9,832     $33,472   $28,646
                                          -------                                ------     -------   -------




             (1)       Includes amortization of
                        deferred financing fees.


    Non-GAAP Financial
     Measures

    Adjusted EBITDA (a non-GAAP measure) is defined in our performance
     measures as earnings before net interest and other expense, taxes,
     depreciation, amortization and goodwill and intangible asset
     impairments.  We believe that Adjusted EBITDA provides useful
     additional information to analysts, creditors, investment bankers and
     management regarding operating performance and debt covenant
     compliance.  Adjusted EBITDA has some inherent limitations in
     measuring operating performance due to the exclusion of certain
     financial elements such as depreciation and amortization and is not
     necessarily comparable to other similarly-titled captions of other
     companies due to potential inconsistencies in the method of

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/nutraceutical-reports-fiscal-2016-q3-results-and-expands-share-repurchase-program-300305209.html

SOURCE Nutraceutical International Corporation